Contract worth approximately $30 million includes a new Proteus®One system and current equipment upgrades
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a contract with the University of Florida Health Proton Therapy Institute (UFHPTI) to install a new Proteus®One system and to upgrade its current proton therapy equipment with IBA’s latest technologies.
IBA will equip UFHPTI with its compact Proteus®One* system, which includes its next-generation precision technologies of Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities as well as the Philips Ambient Experience. The current proton therapy center, which has treated more than 6,000 patients with IBA technology since 2006, will also be upgraded with the latest in IBA technologies, including PBS, CBCT as well as AdaPT Insight, IBA’s platform for adaptive proton therapy and patient-centric workflow.
The contract also includes an operation and maintenance agreement for the Proteus®One system. In total, the contract is worth approximately $30 million to IBA. The UFHPTI expansion and addition of the Proteus®One system is estimated for completion in 2018. The installation of new PBS and CBCT technologies in the existing proton therapy system will start once the new Proteus®One system is installed.
Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted that UFHPTI, one of the early pioneers in proton therapy, has chosen IBA for its expansion by adding our compact Proteus®One system and upgrading its current system. We look forward to continuing our collaboration with them as we work together to advance the use of proton therapy in the fight against cancer.”
Beth Klein, President of IBA PT North America added:“We appreciate our long-standing relationship with the team at UFHPTI and their confidence in IBA to move forward on this significant project; bringing the best that proton therapy has to offer to their patients. IBA’s commitment to customers is to ensure that all of our users are able to upgrade to the most advanced technology over the lifetime of the equipment, without disruption to patient treatment. The IBA Technology Continuum protects customers’ investment and sets IBA apart in the proton therapy industry.”
Nancy Mendenhall, MD, Medical Director of UF Health Proton Therapy Institute said:“The professional support and responsiveness that IBA has demonstrated throughout our 10 years has resulted in the successful treatment of many patients with proton therapy. We are pleased to be able to expand our clinical service with the addition of the Proteus®One system which will enable even more patients to benefit from cutting-edge proton therapy.”